PatientsVille.com Logo


Lmwh Medical Research Studies

Up-to-date List of Lmwh Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Lmwh Medical Research Studies

Rank Status Study
1 Recruiting Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy
Conditions: Deep Venous Thrombosis;   Pulmonary Embolism
Interventions: Drug: Low dose nadroparin;   Drug: Intermediate dose nadroparin;   Drug: Low dose enoxaparin;   Drug: Intermediate dose enoxaparin;   Drug: Low dose dalteparin;   Drug: Intermediate dose dalteparin;   Drug: Fixed low dose tinzaparin;   Drug: Intermediate dose tinzaparin
Outcome Measures: Symptomatic confirmed deep venous thrombosis;   Symptomatic confirmed pulmonary embolism
2 Recruiting Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dalteparin;   Drug: lenalidomide;   Drug: dexamethasone;   Other: laboratory biomarker analysis
Outcome Measures: Number of patients who experienced grade 4 hemorrhage regardless of attribution, or grade 3 hemorrhage that is possibly, probably, or definitely attributable to dalteparin (Arm II);   Possible markers of anti-MM effect;   Toxicities observed at each dose level, in terms of type (organ affected, laboratory determination), severity (by Common Toxicity Criteria [CTC]), time of onset, duration, and reversibility or outcome;   Overall response (CR+PR) calculated for each dose level separately;   Time to progression;   Duration of response;   Anti-thrombotic (syndecan-1, TAT, D-dimer, P-selectin) and anti-myeloma (M-spike and IL-6) marker levels
3 Unknown  The Role of Low Molecular Weight Heparins (Lmwh) Combined With Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Interventions: Drug: Lmwh;   Procedure: TACE
Outcome Measures: time-to-progression(TTP);   The overall response rate;   Overall survival (OS);   bleeding complication rate;   Progression Free Survival (PFS)
4 Unknown  Low-Molecular-Weight Heparin (Lmwh) for Deep Venous Thrombosis (DVT) Prophylaxis
Condition: Deep Venous Thrombosis
Intervention: Drug: Low-Molecular-Weight Heparin
Outcome Measures: We will compare the rates of thrombi formation between the two groups. We will record any clinical significant thrombi or complications that arise from thrombi. We will record any complications related to administration of Lmwh.;   We may find that there is in fact significant benefit to giving prophylaxis to this subset of patients in the form of decreased rates of throbmbus formation and the complications related to thrombi. The risk/benefit ratio should be favorable.
5 Unknown  OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (Lmwh) in Hemodialysis
Conditions: Renal Failure;   Hemodialysis
Interventions: Drug: law molecular weigth heparin;   Drug: unfractioned heparin
Outcome Measures: Levels of osteoprotegerin after administration of UFH or Lmwh used as anticoagulant therapy for hemodialysis;   Secondary aim of the study is to verify the safety of anticoagulation therapy with UFH and Lmwh.
6 Recruiting Comparison of Low-Molecular-Weight Heparin (Lmwh) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism
Condition: This Study Will Provide Data Comparing Safety of Lmwh Versus UFH in the Treatment of Acute PE Cases Who Require Thrombolytic Treatment.
Intervention: Drug: enoxaparin ,alteplase, unfractionated heparin
Outcome Measures: The primary aim of the study is to compare the major hemorrhage risk between the use of Lmwh plus thrombolytic treatment and UFH plus thrombolytic in the treatment of acute massive PE.;   The secondary aim of the study is to compare the minor hemorrhage risk between the use of Lmwh plus thrombolytic treatment and UFH plus thrombolytic in the treatment of acute massive PE.
7 Recruiting Evaluation of the Lmwh Thromboprophylaxis in Pregnancy
Condition: Pregnancy
Outcome Measures: Effect of standard prophylactic dose of Lmwh on coagulation in pregnant women;   Evaluation of the possible influence of Lmwh on the potential risk of spinal hematoma development during neuraxial blockade in pregnancy.
8 Recruiting Effects of Aspirin and Low Molecular Weight Heparin in IVF Outcome.
Condition: To Investigate the Effects of Low Dose Aspirin and Low Molecular Weight Heparin in IVF Out Come
Interventions: Drug: Low molecular weight heparin;   Drug: Low dose aspirin;   Drug: Heparin & aspirin;   Other: NaCl
Outcome Measures: Biological pregnancy test;   Fetal heart/Gestational sac
9 Recruiting PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot
Conditions: Venous Thromboembolism;   Postpartum
Intervention: Drug: Dalteparin Sodium
Outcome Measures: Feasibility of recruitment and trial operations.;   Venous Thromboembolism in the early postpartum period.;   Late symptomatic Venous Thromboembolism;   Death From Venous Thromboembolism;   Major Bleeding or clinically relevant non-major bleeding;   Heparin Induced Thrombocytopenia
10 Unknown  Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD
Conditions: Pulmonary Thromboembolisms;   Pulmonary Embolism
Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA);   Drug: Low Molecular Weight Heparin
Outcome Measures: the composite end point of death from any cause or treatment failure,recurrence of VTE;   improvements of right ventricular functions on echocardiogram and pulmonary artery obstruction on CT angiographs;   serious life threatening bleeding such as cerebral hemorrhage and other major bleeding episodes;   clinical relevant non-major bleedings
11 Not yet recruiting Anticoagulation Length in Cancer Associated Thrombosis
Conditions: Cancer;   Thrombosis;   Venous Thromboembolism;   Deep Vein Thrombosis;   Pulmonary Embolus
Intervention: Drug: Low Molecular Weight Heparin (Lmwh)
Outcome Measures: Number of eligible and recruited patients (target recruitment rate of 30% of eligible patients) over 12 months, and proportion of participants with recurrent VTEs during follow-up.;   Completion of trial protocol;   Quality of life;   Symptom assessment during the study;   Attitudes of clinicians and patients to extended treatment with Lmwh
12 Recruiting PERIOP 2 - A Safety and Effectiveness Study of Lmwh Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.
Condition: Stroke
Interventions: Drug: Dalteparin;   Other: Placebo
Outcome Measures: major thromboembolism;   major bleeding;   minor bleeding;   a composite of major bleeding and major thromboembolic events;   minor thromboembolic events;   overall survival.
13 Unknown  Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients
Conditions: Cancer;   Thrombosis;   Angina Pectoris;   Advanced Solid Malignancy
Outcome Measures: Pharmacokinetics of Low Molecular Weight Heparin (Lmwh) in Cancer patients;   The role of heparanase on the Pharmacokinetics of Low Molecular Weight Heparin (Lmwh) in Cancer patients
14 Unknown  Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss
Condition: Abortion, Habitual
Interventions: Drug: Fragmin P Forte (dalteparin sodium);   Dietary Supplement: Multivitamin supplement
Outcome Measures: ongoing intact pregnancy at 24 weeks of gestation;   late pregnancy complication, defined as at least one of the following: preterm delivery, placenta insufficiency, intrauterine growth retardation, preeclampsia and abruptio placentae;   foetus with structural anomalies;   side effects of dalteparin therapy (e.g. thrombocytopenia, osteoporosis, haemorrhage);   life birth;   preterm delivery (< 37 weeks of gestation)
15 Recruiting The Use of Low Molecular Weight Heparin in Hemodiafiltration
Condition: Chronic Kidney Disease
Interventions: Procedure: At start of the session, at the inlet line;   Procedure: 5 minutes after the start of the session, at the inlet line;   Procedure: At the start of the session, at the outlet line
Outcome Measures: Clearance of uremic toxins, clearance of Lmwh, transmembrane pressure, prefilter pressure, pressure in efferent and afferent bloodline, clotting parameters;   Visual inspection of membrane and circuit
16 Unknown  Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis
Conditions: Deep Vein Thrombosis;   Cancer
Intervention: Drug: low molecular weight heparin
Outcome Measures: Recurrent Deep Vein Thrombosis and/or Pulmonary Embolism;   Minor bleeding;   Death due to cancer
17 Recruiting Use Of Fragmin In Hemodialysis
Condition: Chronic Renal Failure
Intervention: Drug: Fragmin
Outcome Measure: Clotting in Dialyzer
18 Recruiting Effectiveness And Safety of Lmwh Treatment in Cancer Patients Diagnosed With Non-High Risk Venous Thromboembolism
Condition: Venous Thromboembolism
Outcome Measures: Evaluation of effectiveness of Lmwh used in the treatment of thrombosis in cancer patients with VTE regarding new thrombosis.;   Evaluation of effectiveness of Lmwh used in the treatment of thrombosis in cancer patients with VTE regarding resolution.;   Evaluation of effectiveness of Lmwh used in the treatment of thrombosis in cancer patients with VTE regarding bleeding
19 Recruiting Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis
Condition: Acute Pancreatitis
Interventions: Procedure: Continuous regional arterial infusion of low molecular weight heparin in celiac trunk;   Other: General treatment
Outcome Measures: coagulation related complications;   Pancreatic infection;   pancreatic necrosis;   ICU duration;   Hospital duration;   Mortality
20 Recruiting The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Colorectal Cancer
Condition: Colorectal Neoplasms
Interventions: Drug: Nadroparin;   Drug: Placebo
Outcome Measures: the rate of venous thromboembolism, the rate of major and minor bleeding;   3 years disease-free survival;   overall survival

These studies may lead to new treatments and are adding insight into Lmwh etiology and treatment.

A major focus of Lmwh research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Lmwh